Study #2022-0367
A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/1Brachybury) Vaccines (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome
MD Anderson Study Status
Enrolling
Treatment Agent
Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Nogapendekin Alfa, Placebo Administration
Description
This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome. Each of the three injections in Tri-Ad5 vaccine contain a different substance that is in precancer and cancer cells. Injecting these substances may cause the immune system to develop a defense against cancer that recognizes and destroys any precancer and cancer cells that produce these proteins in the future. N-803 may increase immune responses to other vaccines. Giving Tri-Ad5 in combination with immune enhancing N-803 may lower the chance of developing colon and other cancers in participants with Lynch syndrome.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Colorectal Carcinoma, Lynch Syndrome
Study phase:
Phase II
Physician name:
Eduardo Vilar Sanchez
Department:
Clinical Cancer Prevention
For general questions about clinical trials:
1-855-485-3674
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.